Raymond James & Associates Has $57.61 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Raymond James & Associates trimmed its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 3.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 243,688 shares of the medical research company's stock after selling 8,488 shares during the period. Raymond James & Associates owned about 0.48% of Charles River Laboratories International worth $57,608,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Moneta Group Investment Advisors LLC bought a new stake in Charles River Laboratories International during the fourth quarter worth approximately $298,877,000. Meritage Group LP bought a new position in shares of Charles River Laboratories International during the third quarter valued at approximately $173,174,000. Price T Rowe Associates Inc. MD grew its stake in shares of Charles River Laboratories International by 35.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,506,293 shares of the medical research company's stock valued at $505,821,000 after buying an additional 653,790 shares during the last quarter. Norges Bank bought a new position in shares of Charles River Laboratories International during the fourth quarter valued at approximately $97,675,000. Finally, BlackRock Inc. boosted its holdings in shares of Charles River Laboratories International by 8.6% in the second quarter. BlackRock Inc. now owns 5,198,037 shares of the medical research company's stock valued at $1,092,887,000 after purchasing an additional 411,153 shares during the period. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Price Performance

CRL traded up $1.56 during trading on Thursday, reaching $270.93. The company's stock had a trading volume of 497,507 shares, compared to its average volume of 567,248. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73. The firm has a fifty day simple moving average of $242.91 and a two-hundred day simple moving average of $215.59. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00. The company has a market cap of $13.90 billion, a price-to-earnings ratio of 29.37, a PEG ratio of 2.08 and a beta of 1.39.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.39 by $0.07. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The business's revenue was down 7.9% compared to the same quarter last year. During the same quarter last year, the firm earned $2.98 EPS. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on CRL shares. JPMorgan Chase & Co. boosted their price target on Charles River Laboratories International from $270.00 to $280.00 and gave the company an "overweight" rating in a report on Thursday, February 15th. UBS Group upped their target price on Charles River Laboratories International from $270.00 to $290.00 and gave the stock a "buy" rating in a report on Thursday, February 15th. Argus upped their price target on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a "buy" rating in a research report on Monday, March 18th. Robert W. Baird upped their price target on Charles River Laboratories International from $252.00 to $268.00 and gave the stock an "outperform" rating in a research report on Thursday, February 15th. Finally, Evercore ISI upped their target price on Charles River Laboratories International from $260.00 to $265.00 and gave the company an "outperform" rating in a research report on Thursday, February 15th. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $249.64.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares of the company's stock, valued at approximately $626,155.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, VP William D. Barbo sold 4,050 shares of Charles River Laboratories International stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the sale, the vice president now directly owns 22,879 shares of the company's stock, valued at approximately $5,685,431.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Shannon M. Parisotto sold 5,882 shares of the business's stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares of the company's stock, valued at $626,155.20. The disclosure for this sale can be found here. Insiders sold 14,932 shares of company stock valued at $3,693,663 in the last 90 days. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).